<DOC>
	<DOCNO>NCT02018133</DOCNO>
	<brief_summary>The purpose study identify gene responsive paricalcitol ( active vitamin D ) therapy . Scientists find 30 different type cell body respond vitamin D therapy , include blood vessel . Low level vitamin D may reduce amount calcium blood , increase amount parathyroid hormone ( PTH ) cause parathyroid gland ( small gland locate neck ) get big call secondary hyperparathyroidism ( SHPT ) . Also , low level vitamin D may worsen heart disease see dialysis patient . Paricalcitol , man-made active vitamin D , replacement vitamin D prevent treat SHPT . Studies follow patient dialysis find : ( 1 ) difference death rate receive active vitamin D compare activate vitamin D , ( 2 ) survival benefit chronic kidney disease ( CKD ) patient receive paricalcitol , calcitriol ( natural active vitamin D ) . Researchers consider give paricalcitol people ( CKD ) may also prevent slow progression heart disease . Currently , physicians tell well vitamin D work measure PTH concentration . This study aim identify marker blood use determine efficacy Vitamin D therapy .</brief_summary>
	<brief_title>Identification Markers Determining Efficacy Vitamin D Receptor Activator Therapy Stage 3/4 CKD Patients</brief_title>
	<detailed_description>After baseline information laboratory test obtain , subject randomize receive either oral paricalcitol 2 mcg daily 2 week placebo . After washout period 4 week , subject receive paricalcitol receive placebo 2 week receive placebo receive paricalcitol 2 week . A simple blood draw obtain patient day 0 , 1 , 14 treatment arm , also assess side effect end treatment . The blood obtain visit analyze change may occur white blood cell ( WBC ) and/or plasma . These sample test see marker blood change treatment vitamin D. The sample collect temporarily store research laboratory subsequently send separate laboratory ( Genus Systems Company ) batch analysis .</detailed_description>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Chronic kidney disease stage 3/4 PTH : &gt; 70 pg/ml If ACEI/ARB , optimize stable dose Failure provide inform consent Prior active vitamin D oral parenteral treatment , include calcitriol , paricalcitol doxercalciferol Glomerulonephritis require active treatment immunosuppressive therapy Serum phosphorus : &gt; 5.2 mg/dL Serum calcium ( correct albumin ) : &gt; 10.0 mg/dL Clinical unstable medical condition ( CKD ) Use investigational drug within past 30 day 5 halflives , whichever long History malignancy , basal cell carcinoma skin History hypersensitivity vitamin D analog Pregnant nursing ( lactate ) woman Women childbearing potential</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>CKD</keyword>
	<keyword>chronic</keyword>
	<keyword>kidney</keyword>
	<keyword>vitamin D</keyword>
</DOC>